Dyve Biosciences and Moffitt Cancer Center Highlight Encouraging Results for Novel Topical Therapy Targeting Tumor Acidity
Dyve Biosciences and Moffitt Cancer Center Report Promising Study Results for First-of-Its-Kind Topical Therapy Targeting Tumor Acidity Dyve Biosciences, in collaboration with Moffitt Cancer Center, today reported significant study results…
Acumetis Debuts as Unified Brand to Revolutionize Life Sciences Commercialization
Acumetis Launches as a Single Integrated Brand to Transform Life Sciences Commercialization Acumetis – a new global commercialization company for the life sciences industry – launches today. The company, formed…
Travere Wins Full FDA Approval for FILSPARI® in FSGS
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug…
Genmab Reports Safety of Rina-S® Combo with Bevacizumab in Advanced Ovarian Cancer
Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer Genmab A/S announced today new datademonstrating thatrinatabart sesutecan (Rina-S®), an investigational folate receptor…
Orum Therapeutics Names Maria Koehler and Geoff Meyerson to Board
Orum Therapeutics Appoints Dr. Maria Koehler and Geoff Meyerson to Board of Directors Orum Therapeutics, a biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the appointment of…
Biofield Therapy Slows Pancreatic Cancer and Reduces Metastasis, Study Finds
Study Finds Biofield Therapy Slows Pancreatic Cancer Progression and Reduces Metastasis Biofield therapy (BT)—a non-invasive, practitioner-administered therapy—can significantly slow the growth and spread of pancreatic cancer in pre-clinical models, according…
Lineage Forms Scientific Advisory Board
Lineage Announces Formation of Scientific Advisory Board Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today announced…
Natera Reports Positive Interim Analysis from Allogene’s ALPHA3 Trial in LBCL
Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics’ MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today highlighted…
AdaptHealth Refinances Credit Facility, Extends Maturity and Lowers Debt Costs
AdaptHealth Refinances Credit Facility, Extends Maturity and Lowers Debt Costs AdaptHealth Corp., a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced…
Enanta Doses First Patient in Phase 1 Trial of EDP-978 for Urticaria
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria Enanta Pharmaceuticals, Inc., a clinical-stage…
U.S. Grants Priority Review to Ifinatamab Deruxtecan for Previously Treated ES-SCLC After Platinum Therapy
U.S. Grants Priority Review to Ifinatamab Deruxtecan for Previously Treated ES-SCLC Patients After Platinum Therapy Daiichi Sankyo and Merck & Co. have reached an important regulatory milestone with the U.S.…
Johnson & Johnson Highlights TECNIS PureSee IOL Data Showing Enhanced Vision at ASCRS 2026
Johnson & Johnson Presents New TECNIS PureSee IOL Clinical Data Showing Strong Contrast Sensitivity and Extended Vision Range at ASCRS 2026 Johnson & Johnson (NYSE: JNJ) has announced the presentation…